Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy
Por:
Arqueros, C, Gallardo, A, Vidal, S, Osuna-Gómez, R, Tibau, A, Bell, OL, Cajal, T, Lerma, E, Lobato-Delgado, B, Salazar, J, Barnadas, A
Publicada:
1 mar 2024
Resumen:
Currently, therapy response cannot be accurately predicted in HER2-negative breast cancer (BC). Measuring stromal tumour-infiltrating lymphocytes (sTILs) and mediators of the tumour microenvironment and characterizing tumour-infiltrating immune cells (TIICs) may improve treatment response in the neoadjuvant setting. Tumour tissue and peripheral blood samples were retrospectively collected from 118 patients, and sTILs were evaluated. Circulating exosomes and myeloid-derived suppressor cells were determined by flow cytometry. TIICs markers (CD4, CD8, CD20, CD1a, and CD68) were assessed immunohistochemically. High sTILs were significantly associated with pathological complete response (pCR; p = 0.048) and event-free survival (EFS; p = 0.027). High-CD68 cells were significantly associated with pCR in triple-negative (TN, p = 0.027) and high-CD1a cells with EFS in luminal-B (p = 0.012) BC. Cluster analyses of TIICs revealed two groups of tumours (C1 and C2) that had different immune patterns and clinical outcomes. An immunoscore based on clinicopathological variables was developed to identify high risk (C1) or low-risk (C2) patients. Additionally, cluster analyses revealed two groups of tumours for both luminal-B and TNBC. Our findings support the association of sTILs with pCR and show an immunological component in a subset of patients with HER2-negative BC. Our immunoscore may be useful for future escalation or de-escalation treatments.
Filiaciones:
Arqueros, C:
Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona 08041, Spain
Univ Autonoma Barcelona, Fac Med, Dept Med, Barcelona 08035, Spain
Gallardo, A:
Hosp Santa Creu & Sant Pau, Dept Pathol, Barcelona 08041, Spain
Univ Autonoma Barcelona, Fac Med, Dept Morphol Sci, Barcelona 08035, Spain
Inst Invest Biomed St Pau IIB St Pau, Inst Recerca St Pau, CERCA Ctr, Barcelona 08041, Spain
Vidal, S:
Inst Invest Biomed St Pau IIB St Pau, Inst Recerca St Pau, CERCA Ctr, Inflammatory Dis, Barcelona 08041, Spain
Osuna-Gómez, R:
Inst Invest Biomed St Pau IIB St Pau, Inst Recerca St Pau, CERCA Ctr, Inflammatory Dis, Barcelona 08041, Spain
Tibau, A:
Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona 08041, Spain
Bell, OL:
Inst Invest Biomed St Pau IIB St Pau, Inst Recerca St Pau, CERCA Ctr, Translat Med Oncol Lab, Barcelona 08041, Spain
Cajal, T:
Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona 08041, Spain
Lerma, E:
Hosp Santa Creu & Sant Pau, Dept Pathol, Barcelona 08041, Spain
Univ Autonoma Barcelona, Fac Med, Dept Morphol Sci, Barcelona 08035, Spain
Inst Invest Biomed St Pau IIB St Pau, Inst Recerca St Pau, CERCA Ctr, Barcelona 08041, Spain
Lobato-Delgado, B:
Inst Recerca Hosp St Creu & St Pau, CERCA Ctr, Inst Invest Biomed St Pau IIB St Pau, Unitat Genom Malalties Complexes, Barcelona 08041, Spain
Salazar, J:
Inst Invest Biomed St Pau IIB St Pau, Inst Recerca St Pau, CERCA Ctr, Translat Med Oncol Lab, Barcelona 08041, Spain
Barnadas, A:
Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona 08041, Spain
Univ Autonoma Barcelona, Fac Med, Dept Med, Barcelona 08035, Spain
Inst Invest Biomed St Pau IIB St Pau, Inst Recerca St Pau, CERCA Ctr, Translat Med Oncol Lab, Barcelona 08041, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid 28029, Spain
Green Published, gold
|